Perfringolysin O (Theta toxin) (PFO)

Perfringolysin O (PFO), commonly referred to as Theta toxin, is a 53-kDa pore-forming exotoxin secreted by Clostridium perfringens (UniProt P0C2E1). It is a member of the cholesterol-dependent cytolysin (CDC) family, which utilizes membrane cholesterol as a specific receptor for binding and subsequent pore formation (PubMed: 15590777). The toxin's primary biological function is to disrupt host cell membranes, particularly those of leukocytes and erythrocytes, thereby facilitating the spread of the bacteria and evading the host immune response (StatPearls: NBK537030). In the context of disease, PFO is a major virulence factor in gas gangrene (clostridial myonecrosis), where it works synergistically with Alpha toxin to cause extensive tissue destruction and systemic shock (PubMed: 11133755). While there are currently no FDA-approved drugs specifically targeting PFO, therapeutic strategies under investigation include the use of cholesterol-containing liposomes (such as CAL02) as decoys to sequester the toxin and neutralizing antibodies to prevent its oligomerization (PubMed: 25108438). These anti-virulence approaches aim to reduce toxin-mediated damage and improve survival outcomes in severe clostridial infections.

Other names

Theta-toxinClostridium perfringens theta-toxinPFOCholesterol-dependent cytolysinpfoA

Perfringolysin O binds to membrane cholesterol via its C-terminal domain, leading to the assembly of 35-50 monomers into a pre-pore complex; this complex then undergoes a vertical collapse to insert into the lipid bilayer, forming a 25-30 nm aqueous pore that causes osmotic lysis (PubMed: 15590777).